Melanoma antigen preferentially expressed in tumors (142-151)

Melanoma antigen preferentially expressed in tumors (142-151) is a synthetic peptide fragment derived from the well-characterized tumor-associated antigen, MAGE-A1. As a nonapeptide corresponding to amino acids 142 through 151 of the full MAGE-A1 protein sequence, it represents a highly specific epitope recognized by cytotoxic T lymphocytes in the context of human leukocyte antigen (HLA) presentation. The unique immunogenic properties and tumor-restricted expression pattern of MAGE-A1 make this peptide a valuable reagent for studying antigen processing, T cell recognition, and tumor immunology. Its use is central to advancing research on antigen-specific immune responses and the molecular mechanisms underlying tumor immune surveillance.

Immunological assays: The 142-151 fragment is widely utilized as a defined antigenic peptide in T cell activation and recognition assays. Researchers employ it to stimulate and expand antigen-specific CD8+ cytotoxic T lymphocytes from peripheral blood mononuclear cells, enabling precise studies of T cell specificity, functional avidity, and effector function. Its compatibility with ELISPOT, intracellular cytokine staining, and tetramer-based flow cytometry facilitates quantitative and qualitative assessment of immune responses against MAGE-A1-expressing cells, supporting fundamental and translational immunology research.

Epitope mapping: As a model peptide, the MAGE-A1 (142-151) sequence is instrumental in defining minimal T cell epitopes and dissecting the peptide-HLA binding landscape. Its well-characterized interaction with specific HLA alleles enables detailed structural and functional studies of epitope presentation, T cell receptor engagement, and the determinants of immunodominance. This application is crucial for the rational design of peptide-based immunogens and the identification of novel tumor antigens with therapeutic potential.

Antigen processing studies: The peptide serves as a reference substrate in investigations of antigen processing and presentation pathways within antigen-presenting cells. By tracking the generation, transport, and loading of this epitope onto major histocompatibility complex (MHC) molecules, researchers can elucidate the intracellular mechanisms that govern peptide selection and immune visibility of tumor cells. Such studies contribute to a deeper understanding of immune escape and inform strategies to enhance antigen presentation for improved immunotherapeutic targeting.

Peptide-MHC binding analysis: The defined sequence and affinity of this nonapeptide for certain HLA class I molecules make it a valuable tool in biochemical and biophysical assays probing peptide-MHC interactions. Surface plasmon resonance, affinity measurements, and structural studies using this peptide provide insights into the molecular determinants of stable MHC binding and T cell recognition, supporting the development of predictive algorithms and high-throughput screening platforms for immunogenic epitopes.

Synthetic peptide reference: As a chemically defined and sequence-specific reagent, the MAGE-A1 (142-151) peptide is frequently employed as a positive control or calibration standard in peptide synthesis validation, mass spectrometry-based identification, and quality control procedures. Its use ensures reproducibility and accuracy in analytical workflows, particularly in laboratories focused on peptide chemistry, proteomics, and the development of antigen-specific immunoassays. By serving as a benchmark, it supports the standardization and optimization of experimental protocols across diverse research settings.

1. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

2. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

3. Multifunctional peptide-oligonucleotide conjugate promoted sensitive electrochemical biosensing of cardiac troponin I

4. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review